Effects of an 11 β ‐hydroxysteroid dehydrogenase type 1 inhibitor, MK‐0916, in patients with type 2 diabetes mellitus and metabolic syndrome
Year: 2011
Type: article
Study designs: Randomized Controlled Trial, Clinical Trial
Source: Diabetes Obesity and Metabolism
Authors: P. U. Feig, S. Shah, A. Hermanowski‐Vosatka, D. Plotkin, M. S. Springer, S. Donahue, C. Thach, E. J. Klein, E. Lai, K. D. Kaufman
Institution: Merck & Co., Inc., Rahway, NJ, USA (United States)
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W1965576057
